Alumis, Inc. (ALMS)
20.58
+0.52
(+2.59%)
USD |
NASDAQ |
Jun 11, 13:08
Alumis Research and Development Expense (Quarterly) : 80.67M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 80.67M |
| December 31, 2025 | 76.52M |
| September 30, 2025 | 96.92M |
| June 30, 2025 | 107.88M |
| March 31, 2025 | 95.78M |
| December 31, 2024 | 86.38M |
| September 30, 2024 | 87.01M |
| Date | Value |
|---|---|
| June 30, 2024 | 47.80M |
| March 31, 2024 | 41.20M |
| December 31, 2023 | 33.88M |
| September 30, 2023 | 37.47M |
| June 30, 2023 | 32.73M |
| March 31, 2023 | 32.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Nektar Therapeutics | 35.68M |
| Bristol Myers Squibb Co. | 2.238B |
| Amylyx Pharmaceuticals, Inc. | 27.51M |
| Aardvark Therapeutics, Inc. | 16.56M |
| Johnson & Johnson | 3.495B |